Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-hPAM4 Plus Gemcitabine in Advanced Pancreatic Cancer
NCT00603863Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2008
- Primary completion
- Jul 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of clivatuzumab tetraxetan in pancreatic adenocarcinoma (PDAC), sponsored by Gilead Sciences. Started Jan 2008; status: completed.
02
Drugs
clivatuzumab tetraxetan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00603863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00603863.